Clinical Ophthalmology (Aug 2022)
Visual Outcomes of an Enhanced UV Protected Light Adjustable Lens Using a Novel Co-Managed, Open-Access Methodology
Abstract
David V Folden,1– 3 Jennifer R Wong4 1Twin Cities Eye Consultants, Edina, MN, USA; 2North Suburban Eye Specialists, Coon Rapids, MN, USA; 3North Metro Surgery Center, Blaine, MN, USA; 4Praxis Vision, Edina, MN, USACorrespondence: David V Folden, Twin Cities Eye Consultants, 3777 Coon Rapids Blvd NW, Coon Rapids, MN, 55433, USA, Tel +1 763-421-7420, Fax +1 763-421-0730, Email [email protected]: To report on the safety and visual acuity (VA) outcomes using a co-managed, open-access methodology with a second-generation (ActivShieldTM) Light Adjustable Lens (LAL 2.0).Patients and Methods: This retrospective observational case series of consecutive patients implanted with the LAL 2.0 choosing an emmetropic target in at least one eye were included in the study. All patients were co-managed with light treatments occurring at an open-access facility. Exclusion criteria included pathology of the macula and/or cornea with reduced best corrected visual acuity (BCVA). The primary outcome measures were uncorrected distance visual acuity (UDVA), spherical equivalent (SE), and residual cylinder for emmetropic goal eyes at the final 3- to 9-month postoperative visit.Results: Thirty-three patients (62 eyes) were included in the study and implanted with the LAL 2.0. Thirty-three (53.2%) eyes had previous corneal refractive treatment(s) with 22 (66.7%) having no original historical refractive records available. Thirty-six (58.1%) total eyes and 20 (32.3%) postrefractive eyes had an emmetropic refractive target. Of all the emmetropic goal eyes, 35 (97.2%) saw 20/20 or better and 36 (100%) were within ± 0.50 D SE of plano and had a mean cylinder of − 0.15 ± 0.26 D. Of the postrefractive emmetropic goal eyes, 19 (95%) saw 20/20 or better, 20 (100%) were within ± 0.50 D SE of plano and had a mean cylinder of − 0.17 ± 0.28 D.Conclusion: A co-managed, open-access methodology using the LAL 2.0 was safe and efficacious even in challenging postrefractive clinical scenarios.Keywords: ActivShieldTM, light adjustable lens, co-manage, open-access, refractive cataract surgery
